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Abstract
Food and nutrition play an important role in head and neck cancer (HNC) etiology; however, the 
role of carotenoids remains largely undefined. We explored the relation of HNC risk with the 
intake of carotenoids within the International Head and Neck Cancer Epidemiology Consortium. 
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We pooled individual-level data from 10 case–control studies conducted in Europe, North 
America, and Japan. The analysis included 18,207 subjects (4414 with oral and pharyngeal cancer, 
1545 with laryngeal cancer, and 12,248 controls), categorized by quintiles of carotenoid intake 
from natural sources. Comparing the highest with the lowest quintile, the risk reduction associated 
with total carotenoid intake was 39 % (95 % CI 29–47 %) for oral/pharyngeal cancer and 39 % 
(95 % CI 24–50 %) for laryngeal cancer. Intakes of β-carotene equivalents, β-cryptoxanthin, 
lycopene, and lutein plus zeaxanthin were associated with at least 18 % reduction in the rate of 
oral and pharyngeal cancer (95 % CI 6–29 %) and 17 % reduction in the rate of laryngeal cancer 
(95 % CI 0–32 %). The overall protective effect of carotenoids on HNC was stronger for subjects 
reporting greater alcohol consumption (p < 0.05). The odds ratio for the combined effect of low 
carotenoid intake and high alcohol or tobacco consumption versus high carotenoid intake and low 
alcohol or tobacco consumption ranged from 7 (95 % CI 5–9) to 33 (95 % CI 23–49). A diet rich 
in carotenoids may protect against HNC. Persons with both low carotenoid intake and high 
tobacco or alcohol are at substantially higher risk of HNC.
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Background
Head and neck cancer (HNC) includes cancers of the oral cavity, pharynx and larynx, and it 
is one of the most common cancers worldwide [1]. Tobacco and alcohol are the main risk 
factors of HNCs, with human papillomavirus type 16 (HPV-16) being a well-established risk 
factor for oropharyngeal cancer [2].
Furthermore, food and nutrition play an important role in HNC etiology [3]. Several studies 
showed a favorable effect of fruit and vegetables in HNC risk [4–8]. In 2007, the World 
Cancer Research Fund and the American Institute for Cancer Research concluded that 
intakes of non-starchy vegetables and fruit probably protect against cancer of the mouth, 
pharynx, and larynx [3].
Carotenoids from fruit and vegetables may be responsible for some of these favorable 
effects, as they are well-known antioxidants with anti-mutagenic and immune-regulatory 
actions [9]. To date, more than 700 carotenoids have been identified [10]; of these, around 
50 are present in a typical human diet [11]. According to their chemical composition, 
carotenoids can be classified into oxygenated carotenoids (e.g. β-cryptoxanthin, lutein, 
zeaxanthin), known as xanthophylls, and hydrocarbon carotenoids (e.g. alpha-carotene, β-
carotene and lycopene), known as carotenes [12].
The role of carotenoids as important food components in the risk of cancers of the oral 
cavity, pharynx and larynx, however, remains largely undefined. Evidence from 
observational epidemiological studies tends to support an inverse association of HNC risk 
with carotenoid intake [13–22]. Furthermore, there is substantial interest in the potential role 
of specific carotenoids in HNC prevention. However, few case–control studies reported 
associations between the intake of specific carotenoids and HNC [18, 23–31].
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In addition, little is known about the potential for an effect modification by smoking and 
drinking on the relation between carotenoids and HNC. Given the potential antioxidant 
effects of carotenoids, subjects who smoke or consume alcohol may gain more benefit from 
a higher carotenoid intake.
Within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium 
[32], we aimed to explore the relationships between HNC risk and the intake of selected 
carotenoids (β-cryptoxanthin, lycopene, and lutein plus zeaxanthin), as well as combined 
carotenoids (β-carotene equivalents and total carotenoids). Given the large sample size, we 
planned a priori to stratify the results by cancer subtypes, and other covariates of interest, 
including smoking status and alcohol consumption.
Materials and methods
Studies and selection of subjects
This is a pooled analysis of case–control studies participating in the INHANCE Consortium 
[32]—an investigation established in 2004 based on the collaboration of research groups 
leading large, molecular epidemiology studies of HNC—which included populations from 
Europe, North America and Japan in which information on carotenoid intake was available 
from study-specific food frequency questionnaires (FFQs).
The present analysis included 10 case–control studies for which information about 
carotenoid intake and a number of potential confounding variables previously related to 
HNC risk [5, 33–35], was obtained. These studies were conducted in the United States 
[Boston, Buffalo, Los Angeles, Memorial Sloan Kettering Cancer Center (MSKCC) from 
New York City, North Carolina (2002–2006), US Multicenter], Europe [Italy Multicenter, 
Milan (2006–2009), and Switzerland], and Asia [Japan (2001–2005)].
Subjects were included if their tumor had been classified as an invasive cancer of oral cavity, 
oropharynx, hypopharynx, oral cavity or pharynx not otherwise specified, larynx, or HNC 
unspecified. Subjects with cancers of the salivary glands or of the nasal cavity/ear/paranasal 
sinuses were excluded. The International Classification of Diseases coding used for the 
classification into subsites was specified in detail previously [33].
Cases with missing information on the site of origin of their cancer were removed. Subjects 
with missing information on carotenoid intake were removed from the original data. 
Subjects with an implausible (<500 or > 5500 kcal) non-alcohol energy intake or those 
having missing values on non-alcohol energy intake were excluded from the analysis.
The present dataset includes 18,207 subjects: 4414 with oral and pharyngeal cancer, 1545 
with laryngeal cancer, and 12,248 controls. All data were cleaned and checked for internal 
consistency and clarifications were requested from the original investigators when needed. 
All studies included in this pooled analysis had approval from local ethics committees, and 
written informed consent was obtained from all study participants. Study characteristics of 
the 10 studies are reported in the appendix (Table 1).
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Definition of the exposure
For each subject, consumption of several food items in a reference period was assessed using 
study-specific FFQs. Study-specific food composition databases were then used to derive 
from the food items estimates of intakes of total energy and several macro- and micro-
nutrients, including some carotenoids [36].
Information was available from the individual studies on the intakes of the following 
individual carotenoids: β-cryptoxanthin, lycopene, lutein plus zeaxanthin. Combined 
information on more than one carotenoid was provided in some original studies in the form 
of β-carotene equivalents, calculated as:
We also defined total carotenoid intake as the unweighted sum of α-carotene, β-carotene, β-
cryptoxanthin, lycopene, and lutein plus zeaxanthin.
We carried out preliminary checks on carotenoid definitions, reference periods of intake and 
measurement units across studies. We extracted information on carotenoid intake from 
natural sources, and we consistently expressed these intakes on a daily base (μg/day).
To assess the comparability of daily intakes across studies, we inspected the kernel density 
estimation plot representing the study-specific empirical distributions of carotenoid intake 
[37]. We also compared study-specific summary statistics across studies. As preliminary 
checks revealed appreciable differences in carotenoid intake across studies, we computed 
non-alcohol energy-adjusted carotenoid intake within each study [38].
Statistical analysis
Participants were grouped into five categories according to quintiles of ‘non-alcohol energy-
adjusted’ intakes calculated on the overall sample of cases and controls. We estimated the 
odds ratios (OR) and the corresponding 95 % confidence intervals (CI) of oral and 
pharyngeal cancer (including oral, oropharynx, hypopharynx, unspecified oral/pharynx 
cancer), and laryngeal cancer, separately, for each quintile category (compared with the 
lowest quintile, the reference group) using unconditional multiple logistic regression models 
[39].
The following variables were included in the regression equations: age (in 5 year categories), 
gender, education (junior high school or less, some high school, high school graduate, 
technical school/some college, college graduate), ethnicity (black, white/with hispanic, 
others), study center, cigarette smoking status (never, former, current), cigarette smoking 
intensity (≤10, 11–20, >20 cigarettes/day), cigarette smoking duration (≤20, >20 years), 
cigar smoking status (never cigar user, ever smoked ≥100 cigars in a lifetime), pipe smoking 
status (never pipe user, ever smoked ≥100 pipes in a lifetime), alcohol drinking intensity (<1, 
1–2, 3–4, ≥5 drinks/day) and an interaction term between cigarette smoking intensity and 
alcohol drinking intensity.
Leoncini et al. Page 4
Eur J Epidemiol. Author manuscript; available in PMC 2017 August 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
When the p value for heterogeneity between studies was <0.1, we fitted the corresponding 
random intercept-random slope generalized linear mixed models. Separate analyses were 
carried out by anatomical subsite of oral and pharyngeal cancer. For both cancers, stratum-
specific effect estimates were calculated by age, gender, education, geographic region, body 
mass index at time of interview, tobacco consumption, and alcohol consumption. The effect 
of the interaction between alcohol or tobacco consumption and total carotenoid intake was 
also assessed via likelihood ratio tests of significance comparing models including versus 
excluding a combined variable representing available combinations of alcohol (or tobacco) 
and intakes of total carotenoids below or above the median intake on the overall sample.
For total carotenoids, we carried out a sensitivity analysis to investigate the effect of the 
adjustment for four a priori selected nutrients, including vitamin C, vitamin E, 
monounsaturated fatty acids, and polyunsaturated fatty acids. In addition, we evaluated the 
potential interaction effect of those dietary factors with total carotenoids.
All p values were based on two-sided tests. Statistical analyses were performed separately 
for oral and pharyngeal cancer and laryngeal cancer and by anatomical subsite of oral and 
pharyngeal cancer and were done with Stata software (StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP) and the open-source statistical 
computing environment R [40].
Results
The study-specific median and inter-quintile range of unadjusted values of β-carotene 
equivalents, β-cryptoxanthin, lycopene, lutein plus zeaxanthin and total carotenoids, are 
presented in Table 1. The median values were higher in the Italian studies.
Table 2 shows the distribution of 5959 HNC cases and 12,248 controls according to age, 
gender and other selected characteristics, separately for oral and pharyngeal (n = 4414), and 
for laryngeal cancer cases (n = 1545). Overall, cases and controls had similar distributions 
by age and gender whereas controls had a higher education level than cases. Moreover, cases 
were more likely than controls to be cigarette smokers and alcohol drinkers.
Comparing the highest with the lowest quintile, the risk reduction associated with total 
carotenoid intake was 39 % (95 % CI 29–47 %) for oral/pharyngeal cancer and 39 % (95 % 
CI 24–50 %) for laryngeal cancer. Intakes of β-carotene equivalents, β-cryptoxanthin, 
lycopene, and lutein plus zeaxanthin were associated with at least 18 % reduction in the rate 
of oral/pharyngeal cancer (95 % CI 6–29 %) and 17 % reduction in the rate of laryngeal 
cancer (95 % CI 0–32 %) (Table 3). When oral and pharyngeal cancers were evaluated 
separately, the inverse association of carotenoids persisted (data not shown).
Table 4 reports the ORs of oral and pharyngeal cancer for the highest versus the lowest 
quintile of carotenoid intake by category of selected covariates. There was no evidence of 
effect modification by age, gender, BMI and tobacco consumption, whereas appreciable 
heterogeneity of effect estimates was found across strata of education and geographic region 
for β-carotene equivalents and lutein plus zeaxanthin, as the observed protective effect was 
stronger in the European studies and among those with low educational level Appreciable 
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heterogeneity was also detected across strata of alcohol consumption for total carotenoids (p 
< 0.01), with a stronger inverse association for heavy drinkers. The ORs for the fifth quintile 
compared to the first one were 0.79 (95 % CI 0.64–0.97) for never or light drinkers, 0.54 
(95 % CI 0.42–0.70) for moderate drinkers, and 0.40 (95 % CI 0.29–0.56) for heavy 
drinkers. Heterogeneity was also detected across combined strata of alcohol drinking and 
cigarette smoking for total carotenoids.
Table 5 shows the ORs of laryngeal cancer for carotenoid intake in strata of selected 
variables. Similarly to oral and pharyngeal cancer, appreciable heterogeneity was observed 
across strata of geographic region for every nutrient except lycopene, across strata of age for 
lutein plus zeaxanthin, across strata of education for β-carotene equivalents and across strata 
of alcohol consumption for total carotenoids. When the effect of the combined exposure to 
cigarette smoking and alcohol drinking was investigated, heterogeneity across different 
strata was found for β-cryptoxanthin.
Figure 1 shows the combined estimated effects of alcohol or tobacco consumption and total 
carotenoid intake on each type of cancer. For oral and pharyngeal cancer, compared to never 
and light drinkers (<1 drink/day) in the high category of total carotenoid intake (above the 
median), moderate (≥1 to <5 drinks/day) and heavy drinkers (≥5 drinks/day) in either the 
low (equal to or below the median) or the high total carotenoid intake category had higher 
ORs, with values ranging approximately from 2.1 to 10.3, for drinkers of 5 or more drinks 
per day in the low intake category (p for interaction <0.01). Compared to never smokers in 
the high total carotenoid intake category, former and current smokers in either the low or the 
high total carotenoid intake category had higher ORs, with values ranging approximately 
from 1.4 to 7.2, for current smokers of more than 20 cigarettes per day in the low intake 
category (p for interaction <0.001). Similarly, for laryngeal cancer, moderate and heavy 
drinkers or former and current smokers in either category of total carotenoid intake had a 
increased OR, with values of 6.7 and 33.5 in the category with the highest exposure to 
smoking or alcohol and the low exposure to total carotenoids (alcohol, p for interaction 
<0.001; tobacco, p for interaction <0.001).
The sensitivity analyses revealed no consistent interaction effect between the intake of each 
of the a priori selected putative confounding nutrients and total carotenoids, except for the 
case of monounsaturated fatty acids and oral and pharyngeal cancer (p for interaction 0.038). 
Even when the adjustment for the extra nutrient was significant, the point estimates of total 
carotenoid intake on oral and pharyngeal cancer and laryngeal cancer were not altered by the 
inclusion of the extra dietary adjustment variable (data not shown).
Supplementary Table 2 shows the Pearson correlation coefficients between the putative 
confounding nutrients and the individual and combined carotenoids. Correlation coefficients 
were modest, with most absolute values ranging between 0 and 0.40.
Discussion
In this pooled analysis of 10 case–control studies within the INHANCE Consortium on 5959 
cases and 12,248 controls, we found inverse associations between selected and total 
Leoncini et al. Page 6
Eur J Epidemiol. Author manuscript; available in PMC 2017 August 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
carotenoid intakes and oral/pharyngeal and laryngeal cancer. The risk reduction associated 
with total carotenoid intake was about 40 % for both cancers sites, with β-carotene 
equivalents showing the strongest effect (around 45 % of risk reduction) and lycopene the 
weakest (17 % of risk reduction).
To our knowledge, at least one cohort study [41] and 23 case–control studies [13–31, 42–45] 
investigated the association between the intake of carotenoids from dietary sources and HNC 
risk. A few papers based on case–control studies reported associations between the intake of 
specific carotenoids and HNC risk [18, 23–31]. In most [23–27, 29], but not all [18, 28, 30, 
31], of these studies, inverse associations were reported for at least one carotenoid. 
Specifically, an inverse association was reported for α-carotene [24, 26], β-carotene [24, 26, 
29], β-cryptoxanthin [24–27], lycopene [23, 24, 26], and lutein plus zeaxanthin [24, 26]. 
Few of these studies assessed the associations among never-smokers, a group in which 
confounding by smoking, the predominant risk factor for HNC, is avoided [13, 26, 43, 44]. 
Several of these case–control studies were also included in the INHANCE Consortium [13, 
18–21, 24, 26, 27, 30].
Only one cohort study of US postmenopausal women examined dietary intakes of carotene 
in relation to oral, pharyngeal and esophageal cancer [41]. That study found no consistent 
inverse associations for dietary intakes of carotene. However, interpretation of that study 
includes the possibility of a lack of statistical power to detect small but potentially important 
inverse associations because of the relatively small sample size.
Thus, the findings of these studies provide evidence for inverse associations between 
carotenoid intake and HNC risk. Several plausible mechanisms have been reported for such 
a favourable effect of carotenoids [46, 47]. Some of the carotenoids can function as a 
provitamin A, which would have an effect on cellular differentiation and proliferation [48, 
49]. Moreover, carotenoids may act as antioxidants, quenching free radicals, reducing 
damage from reactive oxidant species, and inhibiting lipid peroxidation [46].
The average intake of individual carotenoids, in particular that of lycopene, differs 
substantially across studies. Given the different dietary traditions of the various populations, 
variation in the assessment of the exposure, and the capacity of FFQs in ranking subjects’ 
intakes only, a degree of heterogeneity across studies was expected. However, when we 
restricted our analysis to studies that reported similar levels of intake of the individual 
carotenoids, the inverse association effect persisted.
In the present analysis, the association between intake of carotenoids and HNC risk differed 
by geographic region, with an apparently stronger inverse association in Europe. The reason 
for the heterogeneity between geographic regions is not clear; however, a similar pattern of 
risk was reported in a previous study on vitamin C within the INHANCE Consortium [50]. 
This can be partially explained by the structural differences of the individual questionnaires 
that may affect the calculation of carotenoid intake: number and adequacy of food items 
with respect to the nutrient of interest, frequency type and serving size [51].
Further, we assessed the association between carotenoid intake and HNC, specifically 
comparing results obtained in non-smokers and smokers, as well as in non-drinkers and 
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drinkers [52]. The combination of low carotenoid intake and a high exposure to tobacco or 
alcohol led to 7- to over 30-fold excess risks of oral and pharyngeal, and laryngeal cancer. 
The substantially higher risks observed in this study in heavy alcohol and tobacco 
consumers reporting low carotenoid intake may be due, at least in part, to the role of 
carotenoids against oxidative stress [46]. Cigarette smoking and alcohol drinking, indeed 
cause oxidant stress, which increases DNA damage and, consequently, the malignant 
transformation of normal cells [13].
The inverse association between carotenoids from food sources and HNC risk may not be 
attributable to carotenoid intake per se, but rather may reflect other dietary patterns 
associated with better health or with other unmeasured confounders. For example, the 
consumption of a diet rich in carotenoids may simply reflect a diet characterized by a high 
consumption of fruit and vegetables, which are also abundant in other components, such as 
fibers and other antioxidants. Dietary carotenoids may be also acting as a marker for other 
correlated intakes that may, per se, be protective [53]. In the INHANCE dataset, we 
conducted separate studies on specific nutrients (e.g. vitamin C and, folates) [36, 50], food 
groups and dietary behaviors [35, 54] as they relate to the risk of these malignancies. 
Findings from these studies suggest that higher intakes of folate and vitamin C from foods, 
may protect against cancers of the oral cavity and pharynx, and larynx, after controlling for 
potential confounding factors.
Several factors influence carotenoids bioavailability, absorption, breakdown, transport and 
storage [47, 55, 56]. Further, the interactions between different types of carotenoids and 
other food components may play a role [47]. For example, vitamins C and E and carotenoids 
can act synergistically on the risk of certain cancers [57].
However, the interactions between total carotenoids and the putatively related nutrients were 
not significant in general for either cancer site, with the exception of monounsaturated fatty 
acids and oral and pharyngeal cancer.
Our analysis had several strengths. The large sample size in our study allowed us to examine 
associations within subgroups of the study population with adequate statistical power. In 
most studies the response rate was high, for both cases and controls. We were able to 
adequately control for the potential confounding by tobacco smoking and alcohol drinking, 
having detailed information on smoking and alcohol duration and intensity [58]. We also 
applied uniform criteria to define our exposure of interest. Moreover, analyses by cancer site 
were consistent, which suggests that the action of carotenoids represents a general 
mechanism rather than a site-specific one.
In interpreting our results we acknowledge a few limitations. First, the results may be biased 
by a non differential misclassification of individual intakes of various nutrients due to 
measurement error, and differential misclassification due to recall bias [51]. Additionally, 
residual confounding by under adjustment for alcohol and tobacco intake might have caused 
a biased estimation of the effect of carotenoids of HNC [59, 60]. However, the inverse 
associations were consistent across strata of alcohol and tobacco and, if anything, stronger in 
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heavy drinkers. Consequently, it is unlikely that residual confounding by tobacco and 
alcohol explain our findings.
Secondly, the absence of appreciable confounding by other putatively related nutrients is 
reflected in their generally moderate correlations with carotenoids. Thirdly, although we 
adjusted our estimates for major recognized risk factors for HNC, residual confounding from 
other dietary and non dietary factors (e.g. HPV, physical activity) cannot be excluded. Lastly, 
we did not consider the intakes from multivitamins and beta-carotene supplements; however, 
the bioavailability and absorption of synthetic form of carotenoids are different in 
comparison with to carotenoids from natural sources [61].
In summary, a diet rich in carotenoids may protect against HNC. This is also in line with 
information from a few large studies that analyzed the overall impact of carotenoids in 
relation to HNC. Subjects with both low carotenoid intake and high tobacco or alcohol use 
appear to be at much higher risk of these cancers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Odds ratios and 95 % confidence intervals for combinations of total carotenoids intake with 
tobacco smoking and alcohol drinking among 18,207 subjects: 4414 with oral and 
pharyngeal cancer, 1545 with laryngeal cancer, and 12,248 controls
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